The American College of Rheumatology recommends biosimilar use in new white paper

February 7, 2018, American College of Rheumatology

The American College of Rheumatology (ACR) has published a new white paper, "The Science Behind Biosimilars - Entering a New Era of Biologic Therapy," providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, competition and drug pricing. The paper encourages providers to incorporate these drugs into treatment plans of patients with rheumatic diseases where appropriate.

The FDA has approved nine biosimilar medications, six of which are for treatment of , since the Biologics Price Competition and Innovation Act (BPCI Act) of 2009 was passed in an effort to reduce costs and increase patient's access to biologics. As biosimilar usage increases, an extensive discussion about issues regarding immunogenicity, switching, and patient access has emerged. New recommendations for clinical practice have been made, based on continued evaluation from regulatory agencies and successful administration of biosimilars in Europe. Over the past few years, the ACR has voiced its support for FDA approval measures to ensure the safety of biosimilars as they become available in the U.S. market, including a proposal to require manufacturers to use robust switching studies and support for distinct naming conventions and billing codes to make post-marketing surveillance easier.

"The ACR has closely followed the development, evaluation, and approval processes for biosimilar agents, in addition to observing their successful use in other countries," said Dr. S. Louis Bridges, Jr., MD, PhD, chair of the ACR's Committee on Research and lead author of this paper. "We are now confident that providers can recommend biosimilars as a safe, effective, and affordable option to , where appropriate."

Authors note the only anticipated advantage of a biosimilar over its reference product is lower cost, given that the two drugs should be therapeutically equivalent, and that biosimilars could play a crucial role in fostering competition that keeps high prices at bay. However, the degree to which availability of biosimilars in the U.S. will drive down the cost of biologic therapy remains to be seen. Obstacles for patient accessibility include drug copayments for biosimilars that are nearly as expensive as those for the reference drug. Authors also anticipate pharmacy benefit managers (PBMs) will play a key role, explaining that the lower price of biosimilars could be a negative for their current business model.

"There are a variety of market-based and legislative factors that contribute to the accessibility of biosimilars," said Dr. Angus Worthing, MD, chair of the ACR's Government Affairs Committee and co-author of this paper. "While we have yet to see broad cost-saving benefits in the U.S. marketplace, efforts from health care advocates, legislative measures, and the introduction of additional biosimilar options could help relieve the financial burden of patients using these therapies."

Authors of the paper are hopeful that continued use of biosimilars will improve patient access to biologic drugs, ensuring high quality health care at a lower cost. To maintain exceptional standards of , rheumatologists are urged to maintain a working knowledge of regulatory guidelines and policies, currently approved medications, and evolving research on . The full white paper is available on the ACR website.

Explore further: How should biosimilars be used to treat rheumatic diseases?

Related Stories

How should biosimilars be used to treat rheumatic diseases?

February 7, 2018
Products that are "biosimilar" or interchangeable with a licensed biological product hold considerable promise for the treatment of a variety of medical conditions such as rheumatic diseases, and possibly at a reduced cost. ...

Study examines safety and effectiveness of infliximab biosimilar in patients with inflammatory bowel disease

December 6, 2017
Biosimilars are biologic agents that highly similar to original biomedical medications (originators), but are much cheaper. A new study in Alimentary Pharmacology & Therapeutics found no differences in drug levels and disease ...

Rheumatology providers, FDA leaders discuss biosimilars at national policy briefing

June 21, 2016
Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions ...

Walking a tightrope: Regulators balancing need for safety and flexibility in approvals for new medicines

August 31, 2016
It can be challenging for regulators to keep up with advances related to medical drugs and devices. A new analysis and editorial published in the British Journal of Clinical Pharmacology provide insights on how officials ...

Biosimilar concerns of rheumatology patients being addressed by national program

June 16, 2017
To address the fear and insecurity expressed by rheumatology patients on being switched from a biologic to a biosimilar treatment for their arthritis, the Danish Rheumatism Association has participated in a national programme ...

Biosimilar drugs could create billions in health care savings, study finds

November 3, 2014
Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, ...

Recommended for you

Drug overdose epidemic goes far beyond opioids, requires new policies

November 7, 2018
Most government-funded initiatives to address the overdose epidemic in the United States have targeted opioids specifically and have neglected other drugs that are increasingly implicated in overdoses, such as cocaine and ...

Zebrafish larvae help in search for appetite suppressants

November 2, 2018
Researchers at the University of Zurich and Harvard University have developed a new strategy in the search for psychoactive drugs. By analyzing the behavior of larval zebrafish, they can filter out substances with unwanted ...

FDA OKs powerful opioid pill as alternative to IV painkiller

November 2, 2018
U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals.

Amphetamine-related hospitalizations surged between 2003 and 2015

November 2, 2018
An analysis conducted by Hennepin Healthcare, University of Minnesota School of Public Health and University of Michigan researchers shows amphetamine-related hospitalizations increased more than 270 percent from 2008 to ...

Cocaine-fentanyl overdoses underscore need for more 'test strips' and rapid response

November 1, 2018
Penn Medicine emergency department physicians are calling for more readily available testing strips to identify the presence of fentanyl in patients experiencing a drug overdose, and a rapid, coordinated response among health ...

Combination drug targeting opioid system may help relieve symptoms of major depression

October 29, 2018
Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment. The results of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.